Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Monday that revenues for its fiscal third quarter fell 14 percent year over year, as the COVID-19 pandemic adversely affected its clinical services revenues, diagnostic testing volumes, and product revenues.

For the three months ended April 30, the diagnostics company reported total revenues of $16.9 million compared to $19.7 million in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.